Yokokawa Hideyuki, Kono Teppei, Shidei Hiroaki, Oyama Kunihiro, Ito Yoshitomo, Imaizumi Rie, Miyano Yutaka, Shiozawa Shunichi, Yoshimatsu Kazuhiko
Department of Surgery, Saitama-ken Saiseikai Kurihashi Hospital, 714-6 Koemon, Kuki, Saitama 349-1105 Japan.
Department of Surgery, Tokyo Women's Medical University, Medical Center East, 2-1-10 Nishiogu, Arakawa, Tokyo 116-8567 Japan.
Int Cancer Conf J. 2020 Oct 30;10(1):87-90. doi: 10.1007/s13691-020-00455-x. eCollection 2021 Jan.
Incidence of infusion related reaction (IR) is more common with cetuximab (Cmab) than with panitumumab (Pmab). Although little is known about rechallenge IR with monoclonal antibodies, we experienced a successful rechallenge to Cmab after IR to Pmab. A 67-year-old female patient was scheduled for chemotherapy with mFOLFOX6 plus Pmab against unresectable advanced rectal cancer in the hope of tumor shrinkage. On the first administration of Pmab, she complained of dyspnea with shortness of breath and wheezing, even after premedication with steroids and antihistamines. Her reaction was judged as Grade 2 IR to Pmab. For the next course, we tried Cmab. No IRs were observed. Since then, she has undergone seven further courses of treatment, followed by surgical resection. The patient benefited from administration of Cmab after experiencing IR to Pmab, suggesting this treatment to be an option for patients of this type who experience IR to Pmab.
输注相关反应（IR）在西妥昔单抗（Cmab）治疗中比帕尼单抗（Pmab）更常见。尽管对于单克隆抗体再次激发引起的IR了解甚少，但我们遇到了1例在对Pmab发生IR后成功再次使用Cmab的病例。1例67岁女性患者计划接受mFOLFOX6联合Pmab化疗，以治疗不可切除的晚期直肠癌，期望肿瘤缩小。首次使用Pmab时，即使在使用类固醇和抗组胺药进行预处理后，她仍主诉呼吸困难、呼吸急促和喘息。她的反应被判定为对Pmab的2级IR。在下一疗程中，我们尝试使用Cmab。未观察到IR。从那时起，她又接受了7个疗程的治疗，随后接受了手术切除。该患者在对Pmab发生IR后从Cmab给药中获益，表明这种治疗方法是此类对Pmab发生IR患者的一种选择。
